Aarti Drugs Chairman Prakash M. Patil retires
Aarti Drugs (AARTIDRUGS) said Prakash M. The company is valued at about ₹3,921 crore.
What happened
In a filing with the BSE on 30 September 2026 at 07:50 PM, Aarti Drugs (AARTIDRUGS) said that Prakash M. Patil, Chairman, has retired.
From the filing: "Patil to take early retirement and resign from the positions of Chairman, Managing Director and Chief Executive Officer of the Company, we hereby inform that he has ceased to hold the aforesaid positions with effect from the close of business hours on September 30, 2026."
Company snapshot
Aarti Drugs is a small-cap company in the Healthcare sector, with a market value of about ₹3,921 crore.
The stock last traded at ₹429.7, against a 52-week range of ₹319–₹534 (19.5% below the high).
Before this filing the shares had moved +2.6% over the month and +14.4% over three months. Average daily turnover over the last 20 sessions was about ₹7.98 crore.
Promoters held 54.43% at the end of Q1 FY27, down 0.60% points from the previous quarter; 2.50% of promoter shares were pledged. Foreign institutions owned 1.52% and domestic institutions 10.29%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 591 | 53.9 | 5.91 |
| Q2 FY26 | 653 | 45.3 | 4.95 |
| Q3 FY26 | 602 | 40.5 | 4.44 |
| Q4 FY26 | 720 | 55.2 | 6.05 |
| Q1 FY27 | 703 | 50.2 | 5.49 |
What history shows
This is not the company's first management change disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
Across 100 similar disclosures by other Healthcare companies, shares moved +0.8% on average the next day and +1.8% over five days; 49% of them rose the next day.
Market-wide, 3,837 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 44% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- The appointment of a successor and any change in strategy or guidance.
In the news
Recent coverage elsewhere (links open the original publisher):
- Concord Biotech vs Unichem Laboratories vs Aarti Drugs: Compariso
- Aarti Drugs AGM approves PSOP 2026; institutions vote against plan
- Aarti Drugs announces significant management changes post-AGM
- Aarti Drugs Files Scrutinizer Report and Voting Results for 41st AGM
- Aarti Drugs Holds 41st AGM via Video Conferencing in Line with SEBI Norms
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.